TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
Identifieur interne : 002A94 ( Istex/Corpus ); précédent : 002A93; suivant : 002A95TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
Auteurs : Teck Choon Tan ; Louise Wienholt ; Stephen AdelsteinSource :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2016-10.
Abstract
Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.
Url:
DOI: 10.1111/1756-185X.12792
Links to Exploration step
ISTEX:BB068EA694A4870E19B5F8E3ACB15AD6B562FED9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><author><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name><affiliation><mods:affiliation>Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: teck_choon_tan@ttsh.com.sg</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: teck_choon_tan@ttsh.com.sg</mods:affiliation></affiliation></author><author><name sortKey="Wienholt, Louise" sort="Wienholt, Louise" uniqKey="Wienholt L" first="Louise" last="Wienholt">Louise Wienholt</name><affiliation><mods:affiliation>Clinical Immunology, Royal Prince Alfred Hospital, New South Wales, Sydney, Australia</mods:affiliation></affiliation></author><author><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name><affiliation><mods:affiliation>Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Sydney Medical School University of Sydney, New South Wales, Sydney, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB068EA694A4870E19B5F8E3ACB15AD6B562FED9</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/1756-185X.12792</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002A94</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002A94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><author><name sortKey="Tan, Teck Choon" sort="Tan, Teck Choon" uniqKey="Tan T" first="Teck Choon" last="Tan">Teck Choon Tan</name><affiliation><mods:affiliation>Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: teck_choon_tan@ttsh.com.sg</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: teck_choon_tan@ttsh.com.sg</mods:affiliation></affiliation></author><author><name sortKey="Wienholt, Louise" sort="Wienholt, Louise" uniqKey="Wienholt L" first="Louise" last="Wienholt">Louise Wienholt</name><affiliation><mods:affiliation>Clinical Immunology, Royal Prince Alfred Hospital, New South Wales, Sydney, Australia</mods:affiliation></affiliation></author><author><name sortKey="Adelstein, Stephen" sort="Adelstein, Stephen" uniqKey="Adelstein S" first="Stephen" last="Adelstein">Stephen Adelstein</name><affiliation><mods:affiliation>Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Sydney Medical School University of Sydney, New South Wales, Sydney, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="996">996</biblScope><biblScope unit="page" to="1001">1001</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-10">2016-10</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Teck Choon Tan</name><affiliations><json:string>Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore</json:string><json:string>E-mail: teck_choon_tan@ttsh.com.sg</json:string><json:string>E-mail: teck_choon_tan@ttsh.com.sg</json:string></affiliations></json:item><json:item><name>Louise Wienholt</name><affiliations><json:string>Clinical Immunology, Royal Prince Alfred Hospital, New South Wales, Sydney, Australia</json:string></affiliations></json:item><json:item><name>Stephen Adelstein</name><affiliations><json:string>Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</json:string><json:string>Sydney Medical School University of Sydney, New South Wales, Sydney, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>myositis and related syndromes, Clinical aspects</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>myositis and related syndromes, epidemiology</value></json:item></subject><articleId><json:string>APL12792</json:string></articleId><arkIstex>ark:/67375/WNG-WM32GM47-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</abstract><qualityIndicators><score>7.937</score><pdfWordCount>3045</pdfWordCount><pdfCharCount>20891</pdfCharCount><pdfVersion>1.6</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>593.972 x 782.986 pts</pdfPageSize><pdfWordsPerPage>508</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>241</abstractWordCount><abstractCharCount>1664</abstractCharCount><keywordCount>2</keywordCount></qualityIndicators><title>TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><genre><json:string>article</json:string></genre><host><title>International Journal of Rheumatic Diseases</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1756-185X</json:string></doi><issn><json:string>1756-1841</json:string></issn><eissn><json:string>1756-185X</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>19</volume><issue>10</issue><pages><first>996</first><last>1001</last><total>6</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Original Article</value></json:item><json:item><value>Original Articles</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-WM32GM47-J</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - sarcoidoses. granulomatoses d'etiologie indeterminee. maladies du tissu conjonctif. maladies du tissu elastique. vascularites</json:string></inist></categories><publicationDate>2016</publicationDate><copyrightDate>2016</copyrightDate><doi><json:string>10.1111/1756-185X.12792</json:string></doi><id>BB068EA694A4870E19B5F8E3ACB15AD6B562FED9</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd</licence></availability><date type="published" when="2016-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Teck Choon</forename><surname>Tan</surname></persName><email>teck_choon_tan@ttsh.com.sg</email><affiliation><orgName type="division">Rheumatology, Allergy and Immunology</orgName>
<orgName type="institution">Tan Tock Seng Hospital</orgName>
<address><country key="SG" xml:lang="en">SINGAPORE</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Louise</forename><surname>Wienholt</surname></persName><affiliation><orgName type="division">Clinical Immunology</orgName>
<orgName type="institution">Royal Prince Alfred Hospital</orgName>
<address><settlement>Sydney</settlement>
<region>New South Wales</region>
<country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Stephen</forename><surname>Adelstein</surname></persName><affiliation><orgName type="division">Clinical Immunology</orgName>
<orgName type="institution">Royal Prince Alfred Hospital</orgName>
<address><settlement>Sydney</settlement>
<region>New South Wales</region>
<country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation><affiliation><orgName type="institution">Sydney Medical School University of Sydney</orgName>
<address><settlement>Sydney</settlement>
<region>New South Wales</region>
<country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><idno type="istex">BB068EA694A4870E19B5F8E3ACB15AD6B562FED9</idno><idno type="ark">ark:/67375/WNG-WM32GM47-J</idno><idno type="DOI">10.1111/1756-185X.12792</idno><idno type="unit">APL12792</idno><idno type="toTypesetVersion">file:APL.APL12792.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="pISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><idno type="book-DOI">10.1111/(ISSN)1756-185X</idno><idno type="book-part-DOI">10.1111/apl.2016.19.issue-10</idno><idno type="product">APL</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="996">996</biblScope><biblScope unit="page" to="1001">1001</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2016-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main" xml:id="apl12792-abs-0001"><head>Abstract</head><head>Background</head><p>There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (<hi rend="fc">MSA</hi>). We review the use of a line immunoassay‐based myositis panel incorporating both <hi rend="fc">MSA</hi> and myositis‐associated autoantibodies (<hi rend="fc">MAA</hi>) in a selected population of patients.</p><head>Methods</head><p>A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses.</p><head>Results</head><p>A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (<hi rend="fc">IIM</hi>), 24 patients with suspected interstitial lung disease (<hi rend="fc">ILD</hi>) and 12 patients with suspected systemic autoimmune disease (<hi rend="fc">SAD</hi>). In the myositis group, there were 21 patients diagnosed with <hi rend="fc">IIM</hi> and 18 patients diagnosed with <hi rend="fc">IIM</hi> had a positive myositis panel. Of the 39 patients without <hi rend="fc">IIM</hi>, nine of these patients had a positive myositis panel. In the <hi rend="fc">ILD</hi> group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (<hi rend="fc">ASS</hi>) and five patients with <hi rend="fc">ILD</hi>. In the suspected <hi rend="fc">SAD</hi> group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of <hi rend="fc">IIM</hi> or <hi rend="fc">ILD</hi>‐associated <hi rend="fc">SAD</hi>, four patients with anti‐<hi rend="fc">PL</hi>‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2.</p><head>Conclusions</head><p>The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</p></abstract><textClass><keywords><term xml:id="apl12792-kwd-0001">myositis and related syndromes, Clinical aspects</term><term xml:id="apl12792-kwd-0002">myositis and related syndromes, epidemiology</term></keywords><keywords rend="articleCategory"><term>Original Article</term></keywords><keywords rend="tocHeading1"><term>Original Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="apl12792" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1756-185X</doi><issn type="print">1756-1841</issn><issn type="electronic">1756-185X</issn><idGroup><id type="product" value="APL"></id></idGroup><titleGroup><title sort="INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES" type="main">International Journal of Rheumatic Diseases</title><title type="short">Int J Rheum Dis</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley">10.1111/apl.2016.19.issue-10</doi><copyright ownership="joint"><i>International Journal of Rheumatic Diseases</i> © 2016 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</copyright><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2016-10">October 2016</coverDate></publicationMeta><publicationMeta level="unit" position="100" status="forIssue" type="article"><doi>10.1111/1756-185X.12792</doi><idGroup><id type="unit" value="APL12792"></id></idGroup><countGroup><count number="6" type="pageTotal"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="publisher">© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd</copyright><eventGroup><event agent="SPS" date="2015-10-20" type="xmlCreated"></event><event type="firstOnline" date="2015-12-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2015-12-01"></event><event type="publishedOnlineFinalForm" date="2016-10-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:5.0.6 mode:FullText" date="2017-02-10"></event></eventGroup><numberingGroup><numbering type="pageFirst">996</numbering><numbering type="pageLast">1001</numbering></numberingGroup><correspondenceTo><i>Correspondence</i>: Dr Teck Choon Tan, Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. Email: <email>teck_choon_tan@ttsh.com.sg</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APL.APL12792.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="wordTotal" number="3865"></count></countGroup><titleGroup><title type="main">TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title><title type="shortAuthors">T. C. Tan <i>et al</i>.</title></titleGroup><creators><creator affiliationRef="#apl12792-aff-0001" corresponding="yes" creatorRole="author" xml:id="apl12792-cr-0001"><personName><givenNames>Teck Choon</givenNames> <familyName>Tan</familyName></personName><contactDetails><email>teck_choon_tan@ttsh.com.sg</email></contactDetails></creator><creator affiliationRef="#apl12792-aff-0002" creatorRole="author" xml:id="apl12792-cr-0002"><personName><givenNames>Louise</givenNames> <familyName>Wienholt</familyName></personName></creator><creator affiliationRef="#apl12792-aff-0002 #apl12792-aff-0003" creatorRole="author" xml:id="apl12792-cr-0003"><personName><givenNames>Stephen</givenNames> <familyName>Adelstein</familyName></personName></creator></creators><affiliationGroup><affiliation countryCode="SG" type="organization" xml:id="apl12792-aff-0001"><orgDiv>Rheumatology, Allergy and Immunology</orgDiv> <orgName>Tan Tock Seng Hospital</orgName> <address><country>Singapore</country></address></affiliation><affiliation countryCode="AU" type="organization" xml:id="apl12792-aff-0002"><orgDiv>Clinical Immunology</orgDiv> <orgName>Royal Prince Alfred Hospital</orgName> <address><city>Sydney</city> <countryPart>New South Wales</countryPart> <country>Australia</country></address></affiliation><affiliation countryCode="AU" type="organization" xml:id="apl12792-aff-0003"><orgName>Sydney Medical School University of Sydney</orgName> <address><city>Sydney</city> <countryPart>New South Wales</countryPart> <country>Australia</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="apl12792-kwd-0001">myositis and related syndromes, Clinical aspects</keyword><keyword xml:id="apl12792-kwd-0002">myositis and related syndromes, epidemiology</keyword></keywordGroup><abstractGroup><abstract type="main" xml:id="apl12792-abs-0001"><title type="main">Abstract</title><section xml:id="apl12792-sec-0001"><title type="main">Background</title><p>There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (<fc>MSA</fc>). We review the use of a line immunoassay‐based myositis panel incorporating both <fc>MSA</fc> and myositis‐associated autoantibodies (<fc>MAA</fc>) in a selected population of patients.</p></section><section xml:id="apl12792-sec-0002"><title type="main">Methods</title><p>A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses.</p></section><section xml:id="apl12792-sec-0003"><title type="main">Results</title><p>A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (<fc>IIM</fc>), 24 patients with suspected interstitial lung disease (<fc>ILD</fc>) and 12 patients with suspected systemic autoimmune disease (<fc>SAD</fc>). In the myositis group, there were 21 patients diagnosed with <fc>IIM</fc> and 18 patients diagnosed with <fc>IIM</fc> had a positive myositis panel. Of the 39 patients without <fc>IIM</fc>, nine of these patients had a positive myositis panel. In the <fc>ILD</fc> group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (<fc>ASS</fc>) and five patients with <fc>ILD</fc>. In the suspected <fc>SAD</fc> group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of <fc>IIM</fc> or <fc>ILD</fc>‐associated <fc>SAD</fc>, four patients with anti‐<fc>PL</fc>‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2.</p></section><section xml:id="apl12792-sec-0004"><title type="main">Conclusions</title><p>The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia</title></titleInfo><name type="personal"><namePart type="given">Teck Choon</namePart><namePart type="family">Tan</namePart><affiliation>Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore</affiliation><affiliation>E-mail: teck_choon_tan@ttsh.com.sg</affiliation><affiliation>E-mail: teck_choon_tan@ttsh.com.sg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Louise</namePart><namePart type="family">Wienholt</namePart><affiliation>Clinical Immunology, Royal Prince Alfred Hospital, New South Wales, Sydney, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen</namePart><namePart type="family">Adelstein</namePart><affiliation>Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</affiliation><affiliation>Sydney Medical School University of Sydney, New South Wales, Sydney, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2016-10</dateIssued><dateCreated encoding="w3cdtf">2015-10-20</dateCreated><copyrightDate encoding="w3cdtf">2016</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="words">3865</extent></physicalDescription><abstract>Background: There is increasing recognition of a clinico‐serological correlation between the idiopathic inflammatory myopathies and myositis‐specific autoantibodies (MSA). We review the use of a line immunoassay‐based myositis panel incorporating both MSA and myositis‐associated autoantibodies (MAA) in a selected population of patients. Methods: A retrospective analysis of patients with myositis panel assays performed in 2013 were reviewed and compared against clinical diagnoses. Results: A total of 96 patient samples were evaluated, the clinical indications include 60 patients with suspected idiopathic inflammatory myositis (IIM), 24 patients with suspected interstitial lung disease (ILD) and 12 patients with suspected systemic autoimmune disease (SAD). In the myositis group, there were 21 patients diagnosed with IIM and 18 patients diagnosed with IIM had a positive myositis panel. Of the 39 patients without IIM, nine of these patients had a positive myositis panel. In the ILD group, 10 of 24 patients had a positive myositis panel; of these, two were diagnosed anti‐synthetase syndrome (ASS) and five patients with ILD. In the suspected SAD group, three had positive myositis panel and all did not appear associated with their final diagnoses. In patients with a clinical diagnosis of IIM or ILD‐associated SAD, four patients with anti‐PL‐12 were detected, three patients with anti‐signal recognition protein, two patients with anti‐Jo‐1, and two patients with anti‐Mi2. Conclusions: The myositis panel is an objective investigative modality with a sensitivity of 80.00% and a specificity of 75.76% in a setting of high pretest clinical suspicion.</abstract><subject><genre>keywords</genre><topic>myositis and related syndromes, Clinical aspects</topic><topic>myositis and related syndromes, epidemiology</topic></subject><relatedItem type="host"><titleInfo><title>International Journal of Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Int J Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Original Article</topic><topic>Original Articles</topic></subject><identifier type="ISSN">1756-1841</identifier><identifier type="eISSN">1756-185X</identifier><identifier type="DOI">10.1111/(ISSN)1756-185X</identifier><identifier type="PublisherID">APL</identifier><part><date>2016</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>996</start><end>1001</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0001"><titleInfo><title>Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria</title></titleInfo><name type="personal"><namePart type="given">FL</namePart><namePart type="family">Mastaglia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BA</namePart><namePart type="family">Phillips</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28, 723–41.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>723</start><end>41</end></extent></part><relatedItem type="host"><titleInfo><title>Rheum Dis Clin North Am</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>723</start><end>41</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0002"><titleInfo><title>The evolving spectrum of polymyositis and dermatomyositis‐ moving towards clinicoserologic syndromes: a critical review</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Tansley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Guawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tansley S, Guawardena H (2014) The evolving spectrum of polymyositis and dermatomyositis‐ moving towards clinicoserologic syndromes: a critical review. Clin Rev Allergy Immunol 47, 264–73.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>264</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Rev Allergy Immunol</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>264</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0003"><titleInfo><title>Myositis autoantibodies</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Casciola‐Rosen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Manmen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Casciola‐Rosen L, Manmen AL (2012) Myositis autoantibodies. Curr Opin Rheumatol 24, 602–8.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>602</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Rheumatol</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>602</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0004"><titleInfo><title>Antibody to signal recognition particle in polymyositis</title></titleInfo><name type="personal"><namePart type="given">IN</namePart><namePart type="family">Targoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AE</namePart><namePart type="family">Johnson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33, 1361–70.</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1361</start><end>70</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1361</start><end>70</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0005"><titleInfo><title>Anti‐signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">AH</namePart><namePart type="family">Kao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Lacomis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Lucas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kao AH, Lacomis D, Lucas M et al. (2004) Anti‐signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50 (1), 209–15.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>209</start><end>15</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>209</start><end>15</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0006"><titleInfo><title>Anti‐signal recognition particle autoantibodies: marker of a necrotising myopathy</title></titleInfo><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Hengstman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">ter Laak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Vree Egberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hengstman GJ, ter Laak HJ, Vree Egberts WT et al. (2006) Anti‐signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65, 1635–8.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1635</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1635</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0007"><titleInfo><title>A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathy</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Christopher‐Stine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LA</namePart><namePart type="family">Casciola‐Rosen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Hong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Christopher‐Stine L, Casciola‐Rosen LA, Hong G et al. (2010) A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathy. Arthritis Rheum 62, 2757–66.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2757</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2757</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0008"><titleInfo><title>Autoantibodies against 3‐hydroxy‐3‐ methylglutaryl‐coenzyme A reductase in patients with statin‐associated autoimmune myopathy</title></titleInfo><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Mammen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Chung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Christopher‐Stine</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mammen AL, Chung T, Christopher‐Stine L et al. (2011) Autoantibodies against 3‐hydroxy‐3‐ methylglutaryl‐coenzyme A reductase in patients with statin‐associated autoimmune myopathy. Arthritis Rheum 63, 713–21.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>713</start><end>21</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>713</start><end>21</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0009"><titleInfo><title>Idiopathic inflammatory myopathies and the anti‐synthetase syndrome: a comprehensive review</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mahler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Fritzler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti‐synthetase syndrome: a comprehensive review. Autoimmun Rev 13, 367–71.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>367</start><end>71</end></extent></part><relatedItem type="host"><titleInfo><title>Autoimmun Rev</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>367</start><end>71</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0010"><titleInfo><title>Anti‐Ro52 antibodies frequently co‐occur with anti‐Jo‐1 antibodies in sera from patients with idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Rutjes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Vree Egberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Jongen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rutjes SA, Vree Egberts WT, Jongen P et al. (1997) Anti‐Ro52 antibodies frequently co‐occur with anti‐Jo‐1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109, 32–40.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>32</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Immunol</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>32</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0011"><titleInfo><title>Myositis‐specific and myositis‐associated antibodies in a series of eighty‐eight Mediterranean patients with idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Selva‐O'Callaghan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Labrador‐Horrillo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Solans‐Laque</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Selva‐O'Callaghan A, Labrador‐Horrillo M, Solans‐Laque R et al. (2006) Myositis‐specific and myositis‐associated antibodies in a series of eighty‐eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 55, 791–8.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>791</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>791</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0012"><titleInfo><title>International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti‐nuclear antibodies</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Agmon‐Levin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Damoiseaux</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Kallenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Agmon‐Levin N, Damoiseaux J, Kallenberg C et al. (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti‐nuclear antibodies. Ann Rheum Dis 73 (1), 17–23.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>17</start><end>23</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>17</start><end>23</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0013"><titleInfo><title>A47: progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Pikington</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tjärnlund</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bottai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pikington C, Tjärnlund A, Bottai M et al. (2014) A47: progress report on the development of new classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis Rheumatol 66 (Suppl. 11), S70–1.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 11</number></detail><extent unit="pages"><start>S70</start><end>1</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheumatol</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 11</number></detail><extent unit="pages"><start>S70</start><end>1</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0014"><titleInfo><title>Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Dobloug</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Garen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bitter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dobloug C, Garen T, Bitter H et al. (2015) Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 74, 1551–6.</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>1551</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>74</number></detail><extent unit="pages"><start>1551</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0015"><titleInfo><title>Common and distinct clinical & features in adult patients with anti‐aminoacyl‐tRNA synthetase antibodies: heterogeneity within the syndrome</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Hamaguchi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Fujimoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Matsushita</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hamaguchi Y, Fujimoto M, Matsushita T et al. (2013) Common and distinct clinical & features in adult patients with anti‐aminoacyl‐tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 8, e60442.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>e60442</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS ONE</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>e60442</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0016"><titleInfo><title>Myositis‐specific autoantibodies: their clinical and pathogenic significance in disease expression</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gunawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZE</namePart><namePart type="family">Betteridge</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">McHugh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis‐specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 48, 607–12.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>607</start><end>12</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>607</start><end>12</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0017"><titleInfo><title>Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Watanabe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Handa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Tanizawa</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watanabe K, Handa T, Tanizawa K et al. (2011) Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 105, 1238–47.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>1238</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>Respir Med</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>1238</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0018"><titleInfo><title>Serological associations and subtypes of diffuse parenchymal lung disease in scleroderma spectrum disorders and idiopathic inflammatory myopathy</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Gunawardena</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Robinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZE</namePart><namePart type="family">Betteridge</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gunawardena H, Robinson G, Betteridge ZE et al. (2007) Serological associations and subtypes of diffuse parenchymal lung disease in scleroderma spectrum disorders and idiopathic inflammatory myopathy. Rheumatology 46 (Suppl. 1), i76.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 1</number></detail><extent unit="pages"><start>i76</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><detail type="issue"><caption>no.</caption><number>Suppl. 1</number></detail><extent unit="pages"><start>i76</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0019"><titleInfo><title>Patients with non‐Jo‐1 anti‐tRNA‐synthetase autoantibodies have worse survival than Jo‐1 positive patients</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Aggarwal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Cassidy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Fertig</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aggarwal R, Cassidy E, Fertig N et al. (2014) Patients with non‐Jo‐1 anti‐tRNA‐synthetase autoantibodies have worse survival than Jo‐1 positive patients. Ann Rheum Dis 73 (1), 227–32.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>227</start><end>32</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>227</start><end>32</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0020"><titleInfo><title>The clinical phenotype associated with myositis‐specific and associated autoantibodies: a meta‐analysis revisiting the so‐called antisynthetase syndrome</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Lega</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Fabien</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Reynaud</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lega JC, Fabien N, Reynaud Q et al. (2014) The clinical phenotype associated with myositis‐specific and associated autoantibodies: a meta‐analysis revisiting the so‐called antisynthetase syndrome. Autoimmun Rev 13, 883–91.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>883</start><end>91</end></extent></part><relatedItem type="host"><titleInfo><title>Autoimmun Rev</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>883</start><end>91</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0021"><titleInfo><title>Short‐term and long‐term outcome of anti‐Jo1‐positive patients with anti‐Ro52 antibody</title></titleInfo><name type="personal"><namePart type="given">I</namePart><namePart type="family">Marie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PY</namePart><namePart type="family">Hatron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Dominique</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marie I, Hatron PY, Dominique S et al. (2012) Short‐term and long‐term outcome of anti‐Jo1‐positive patients with anti‐Ro52 antibody. Semin Arthritis Rheum 41, 890–9.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>890</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>890</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0022"><titleInfo><title>Characteristics of interstitial lung disease in SS‐A positive/Jo‐1 positive inflammatory myopathy patients</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Váncsa</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Csípő</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Németh</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Váncsa A, Csípő I, Németh J et al. (2009) Characteristics of interstitial lung disease in SS‐A positive/Jo‐1 positive inflammatory myopathy patients. Rheumatol Int 29, 989–94.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>989</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatol Int</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>989</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="apl12792-cit-0023"><titleInfo><title>In patients with antisynthetase syndrome the occurrence of anti‐Ro/SSA antibodies causes a more severe interstitial lung disease</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">La Corte</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Lo Mo Naco</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Locaputo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">La Corte R, Lo Mo Naco A, Locaputo A et al. (2006) In patients with antisynthetase syndrome the occurrence of anti‐Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39, 249–53.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>249</start><end>53</end></extent></part><relatedItem type="host"><titleInfo><title>Autoimmunity</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>249</start><end>53</end></extent></part></relatedItem></relatedItem><identifier type="istex">BB068EA694A4870E19B5F8E3ACB15AD6B562FED9</identifier><identifier type="ark">ark:/67375/WNG-WM32GM47-J</identifier><identifier type="DOI">10.1111/1756-185X.12792</identifier><identifier type="ArticleID">APL12792</identifier><accessCondition type="use and reproduction" contentType="copyright">International Journal of Rheumatic Diseases © 2016 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-WM32GM47-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002A94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:BB068EA694A4870E19B5F8E3ACB15AD6B562FED9
|texte= TEST performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia
}}
| This area was generated with Dilib version V0.6.33. |  |